PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing.

dc.contributor.author

Landstrom, AP

dc.contributor.author

Adekola, BA

dc.contributor.author

Bos, JM

dc.contributor.author

Ommen, SR

dc.contributor.author

Ackerman, MJ

dc.date.accessioned

2020-04-01T13:41:42Z

dc.date.available

2020-04-01T13:41:42Z

dc.date.issued

2011-01

dc.date.updated

2020-04-01T13:41:42Z

dc.description.abstract

BACKGROUND:hypertrophic cardiomyopathy (HCM) is a major cause of sudden death in young athletes and one of the most common inherited cardiovascular diseases, affecting 1 in 500 individuals. Often viewed as a disease of the cardiac sarcomere, mutations in genes encoding myofilament proteins are associated with disease pathogenesis. Despite a clinically available genetic test, a significant portion of HCM patients remain genetically unexplained. We sought to determine the spectrum and prevalence of mutations in PLN-encoded phospholamban in a large cohort of HCM cases as a potential cause of mutation-negative HCM. METHODS:comprehensive genetic interrogation of the promoter and coding region of PLN was conducted using polymerase chain reaction, denaturing high-performance liquid chromatography, and direct DNA sequencing. RESULTS:one L39X nonsense mutation was identified in 1 of 1,064 HCM proband cases with a family history of HCM, previously found to be negative for the current HCM genetic test panel. This mutation cosegregated with incidence of HCM in a multigenerational family. Compared with similar studies, we identified an overall yield of PLN-HCM mutations of 0.65%, similar to 3 genes that are part of current HCM genetic test panels. We did not observe any PLN coding sequence genetic variation in 600 reference alleles. CONCLUSIONS:overall, mutations in PLN are rare in frequency, yet the small size of the genetic locus may make it amenable to inclusion on HCM gene test panels, especially because the frequency of background genetic variation among otherwise healthy subjects appears negligible. The exact role of mutations in PLN and other calcium-handling proteins in the development of HCM warrants further investigation.

dc.identifier

S0002-8703(10)00675-7

dc.identifier.issn

0002-8703

dc.identifier.issn

1097-6744

dc.identifier.uri

https://hdl.handle.net/10161/20326

dc.language

eng

dc.publisher

Elsevier BV

dc.relation.ispartof

American heart journal

dc.relation.isversionof

10.1016/j.ahj.2010.08.001

dc.subject

Humans

dc.subject

Cardiomyopathy, Hypertrophic

dc.subject

Genetic Predisposition to Disease

dc.subject

Calcium-Binding Proteins

dc.subject

DNA

dc.subject

Electrocardiography

dc.subject

Chromatography, High Pressure Liquid

dc.subject

Retrospective Studies

dc.subject

Polymerase Chain Reaction

dc.subject

Pedigree

dc.subject

Mutation

dc.subject

Alleles

dc.subject

Adult

dc.subject

Female

dc.subject

Male

dc.subject

Genetic Testing

dc.title

PLN-encoded phospholamban mutation in a large cohort of hypertrophic cardiomyopathy cases: summary of the literature and implications for genetic testing.

dc.type

Journal article

duke.contributor.orcid

Landstrom, AP|0000-0002-1878-9631

pubs.begin-page

165

pubs.end-page

171

pubs.issue

1

pubs.organisational-group

School of Medicine

pubs.organisational-group

Cell Biology

pubs.organisational-group

Pediatrics, Cardiology

pubs.organisational-group

Duke

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Pediatrics

pubs.organisational-group

Clinical Science Departments

pubs.publication-status

Published

pubs.volume

161

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Manuscript - PLN in HCM.pdf
Size:
570.52 KB
Format:
Adobe Portable Document Format
Description:
Published version